XBIO · Xenetic Biosciences Inc

-

Please sign in to comment on XBIO

1 Comment

Admin

4 years, 12 months ago

Xenetic Biosciences, Inc is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.

From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.9.

Xenetic Biosciences, Inc's total revenue rose by 786.7% to $151K since the same quarter in the previous year.

Its net income has dropped by 2.5% to $-1M since the same quarter in the previous year.

Finally, its free cash flow grew by 43.2% to $-954K since the same quarter in the previous year.

Based on the above factors, Xenetic Biosciences, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US9840155033
Sector	Healthcare
Industry	Biotechnology

Beta	2.32
Market Cap	6M
PE Ratio	None
Target Price	40
Dividend Yield	None

ABOUT

Xenetic Biosciences Inc

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIO · Xenetic Biosciences Inc

-

Xenetic Biosciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Xenetic Biosciences Inc using a moving average strategy